Investors

News Releases

Date Title  
Toggle Summary POZEN Reports Third Quarter 2015 Results
Strategic Merger with Tribute Pharmaceuticals Still on Track to Close in December 2015 Commercial Launch Preparation Efforts for YOSPRALA TM Well Underway CHAPEL HILL, N.C. --(BUSINESS WIRE)--Nov. 9, 2015-- POZEN Inc. (NASDAQ: POZN) , today announced results for the third quarter ended September
Toggle Summary POZEN to Present at the Ladenburg Thalmann Healthcare Conference
CHAPEL HILL, N.C. --(BUSINESS WIRE)--Sep. 15, 2015-- POZEN Inc. (NASDAQ: POZN), a specialty pharmaceutical company, today announced that certain members of the executive management team will participate in the Ladenburg Thalmann Healthcare Conference to be held September 29, 2015 in New York .
Toggle Summary RETRANSMISSION: Tribute Schedules Special Shareholder Meeting for February 1, 2016
MILTON, ONTARIO -- (Marketwired) -- 12/29/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX) (OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty    pharmaceutical company with a primary focus on the acquisition, licensing,    development and promotion
Toggle Summary Tribute Announces Third Quarter 2015 Results
    Revenue Up 133%, EBITDA Up 281% Over    Comparative Period     MILTON, ONTARIO -- (Marketwired) -- 11/09/15 -- Tribute Pharmaceuticals Canada    Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a diversified    healthcare company with a primary focus on the acquisition,
Toggle Summary Tribute Comments on Trading Activity at the Request of IIROC
MILTON, ONTARIO -- (Marketwired) -- 09/29/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the
Toggle Summary Tribute Pharmaceuticals Added to the S&P/TSX Venture Composite Index
MILTON, ONTARIO -- (Marketwired) -- 04/15/15 -- Tribute Pharmaceuticals Canada Inc. (TSX VENTURE: TRX )(OTCQX: TBUFF ) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela®, Proferrin® and 13 Additional Products MILTON, ONTARIO--(Marketwired - June 17, 2015) - NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of Medical Futures Inc., a Canadian Specialty Pharmaceutical Company
Includes Canadian Rights to Durela(R), Proferrin(R) and 13 Additional Products MILTON, ONTARIO -- (Marketwired) -- 06/17/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF)(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition,
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor(R) and Commercial Expansion into U.S. Market
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO -- (Marketwired) -- 05/21/15 -- Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF )(TSX VENTURE:TRX) ("Tribute" or the "Company"), a specialty pharmaceutical company with a primary focus on the acquisition, licensing,
Toggle Summary Tribute Pharmaceuticals Announces Acquisition of U.S. Rights to Fibricor®, Commercial Expansion into U.S. Market and Completion of $12 Million Equity Financing
- William Maichle Hired as President of U.S. Operations MILTON, ONTARIO--(Marketwired - May 21, 2015) - NOT FOR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES Tribute Pharmaceuticals Canada Inc. (TSX VENTURE:TRX)(OTCQX:TBUFF) ("Tribute" or the "Company"), a specialty

Copyright West LLC. Minimum 15 minutes delayed.